Abstract 2208P
Background
Pulmonary lymphoepithelioma-like carcinoma (PLELC) is a rare form of non-small cell lung cancer which is frequently associated with EBV infection and displays high levels of immune cell infiltration. Immunotherapy, thus, is an attractive therapeutic strategy for the disease but the treatment response has been inconsistent, indicating a gap in our understanding of the tumor microenvironment (TME) of PLELC.
Methods
Imaging mass cytometry was used in this study to map the different cellular components and interactions in 33 PLELCs at different stages (19 early-stage, 6 medium-stage, and 8 advanced-stage).
Results
Component analysis showed differential B and Treg cell composition in the TME as cancer progresses. In spatial analyses, we discovered a convergent melting trend of immune cell distribution across different stages in the tumor and non-tumor regions (p<0.05). We also identified anti-tumor immunity markers assigned to specific cellular interactions (p<0.01). In the neighborhood analysis, we found that myeloid cells near the tumor may attenuate the ability of antigenic immune responses. Furthermore, we identified two spatial structures within the TME that could impact the infiltration of immune cells and the relapse of patients, and disease relapse in patients is associated with the level of immune cells inside the tumor region (p<0.01) and fibroblasts surrounding the tumor.
Conclusions
Our findings indicate that TME is heterogeneous and dynamic along the disease progression of PLELC such that cellular components, spatial interactions, and immune cell infiltration may play a significant role in disease recurrence. Moreover, profiling the TME may be helpful for understanding and selecting different immune treatments.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2172P - Development and evaluation of the usefulness of an immune-related adverse events interview application
Presenter: AKIKO YANO
Session: Poster session 07
2173P - Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital
Presenter: Niamh Cunningham
Session: Poster session 07
2174P - The impact of exposure to antibiotic (ATB) and proton pump inhibitor (PPI) therapy on immune checkpoint inhibitor (ICI) treatment on overall survival (OS): A population-based study
Presenter: Lawson Eng
Session: Poster session 07
2175P - Sex and age-related differences in immunotherapy-induced toxicities
Presenter: Mafalda Teixeira da Costa
Session: Poster session 07
2176P - Rechallenge of immune checkpoint inhibitors after immune-related adverse events: A systematic review
Presenter: Jin Young Kim
Session: Poster session 07
2177P - Immunotherapy adverse events association with inflammation scores: A real-world data analysis from a Portuguese hospital
Presenter: Catarina Fernandes
Session: Poster session 07
2179P - Prospective monitoring of autoimmune events in cancer immunotherapy patients: A report on the first 658 patients in the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07
2180P - Detrimental effect of an early exposure to antibiotics on the outcomes of immunotherapy in a multi-tumor cohort of patients
Presenter: Víctor Albarrán
Session: Poster session 07
2181P - Effect of different corticosteroid treatment strategies on checkpoint inhibitors pneumonitis outcomes
Presenter: Hui Guo
Session: Poster session 07
2182P - Patient involvement to improve prospective follow-up: Quality of life data after cancer immunotherapy from the PRAISE study
Presenter: Eden Sebbag
Session: Poster session 07